Model Teaches Skin Lesion Diagnosis and Removal

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

BRISTOL, UK--A life-size model of a face with the look, feel, and color of real tissue allows medical students to recognize a wide variety of skin lesions--basal cell carcinomas, malignant melanomas, cysts, and warts--and practice a number of procedures, including lesion removal and planning of incisions.

BRISTOL, UK--A life-size model of a face with the look, feel, and color of real tissue allows medical students to recognize a wide variety of skin lesions--basal cell carcinomas, malignant melanomas, cysts, and warts--and practice a number of procedures, including lesion removal and planning of incisions.

The face is one of a line of soft-tissue simulators produced by Limbs and Things Limited. The company’s first product was a heart model designed to demonstrate atrial septal defect, including a patch that can be stitched on to the defect and removed, allowing for re-use of the simulator. Other models for use in minor surgery workshops include an ingrown toenail simulator and an intramuscular pad for practicing injections.

Limbs and Things Limited can be reached at Radnor Business Centre, Radnor Road, Horfield, Bristol, UK BS7 8QS. Telephone: +44 117 944 6466; fax: +44 117 994 6222.

Recent Videos
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
Related Content